dvt current concept
TRANSCRIPT
![Page 1: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/1.jpg)
DVTDVTCurrent ConceptsCurrent Concepts
Dr Saeed Al-ShomimiKing Fahad Hospital of University
Khobar – Saudi Arabia2005
![Page 2: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/2.jpg)
Venous Thromboembolism
StasisStasis
Activation of CoagulationActivation of Coagulation
Vessel DamageVessel Damage
Virchow's Triad
![Page 3: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/3.jpg)
Etiology
![Page 4: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/4.jpg)
FREQUENTLY ENCOUNTEREDFREQUENTLY ENCOUNTERED
Prolonged fever + recumbency Lengthy major surgery Orthopaedic / Urologic Massive trauma Pregnancy Long standing v.vs hepatitis
![Page 5: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/5.jpg)
ETIOLOGY
Obscure ZonesObscure Zones
![Page 6: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/6.jpg)
AnesthesiaAnesthesia
general anesthesia have a 5X increased risk of DVT compared with patients receiving epidural anesthesia for the same surgical procedure.
![Page 7: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/7.jpg)
Blood surface antigensBlood surface antigens
Type A blood is associated with lower levels of antithrombin III and higher levels of factor VIII than type O blood.
Women of reproductive age with type A blood are 4 times as likely to develop DVT.
This association of risk with blood type A does not extend to older men or to women past reproductive age
![Page 8: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/8.jpg)
CancerCancer
Malignancy is an important risk factor for DVT, and spontaneous DVT without an obvious cause is an important marker for possible occult malignancy.
In 38% of cases of concomitant cancer and DVT, the DVT is detected first.
![Page 9: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/9.jpg)
The relative risk for cancer is 19 times higher for patients younger than 50 years who have had DVT than for those without a history of DVT.
16% of patients with angiographically proven PE are diagnosed with cancer within 2 years.
![Page 10: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/10.jpg)
Strokes and neurotraumaStrokes and neurotrauma
common after stroke or neurological trauma.
Without prophylaxis, half the patients develop acute DVT within 5 days following a stroke.
Head trauma may cause disseminated intravascular coagulation, and DVT.
![Page 11: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/11.jpg)
40% of postoperative neurosurgical patients develop DVT.
Stroke patients with a single paretic leg develop DVT in 60% of the paralyzed legs but in only 7% of the nonparalyzed ones.
![Page 12: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/12.jpg)
ChemotherapyChemotherapy
Many types of chemotherapy increase the risk of DVT and PE
↓ the levels of circulating anticoagulants such as antithrombin III or protein C or S
↑procoagulants such as von Willebrand factor
depress fibrinolytic activity.
![Page 13: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/13.jpg)
Coagulopathy Coagulopathy
Protein C Protein S Antithrombin III
15% of the cases of DVT
![Page 14: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/14.jpg)
Heart diseaseHeart disease Acute MI and CHF increase the likelihood of
DVT and PE, independent of bed rest or immobilization.
Patients with acute MI who are not receiving anticoagulation have a 26-38% rate of DVT.
![Page 15: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/15.jpg)
Inflammatory bowel diseaseInflammatory bowel disease
Patients with ulcerative colitis or Crohn disease are at increased risk for DVT and PE because of increased fibrinogen, factor VIII, and platelet activity and depressed levels of antithrombin III and alpha2-macroglobulin.
![Page 16: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/16.jpg)
Prior DVTPrior DVT Patients with a prior episode of DVT are 5 times
more likely to develop new DVT compared with patients with no prior episodes of DVT.
Prior DVT increases the risk of new postoperative DVT from 26% to 68%.
A history of prior clinically apparent PE increases the risk of new postoperative DVT to nearly 100%.
![Page 17: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/17.jpg)
Autoimmune VasculitisAutoimmune Vasculitis
Behcet’s disease Lupus antibodies Anticardiolipin AB Antiphospholipid AB ASMC AB
Especially in young with no
apparent cause
![Page 18: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/18.jpg)
INVESTIGATIONS
![Page 19: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/19.jpg)
LABLAB
PT ,PTT , INR ESR D-dimer ABG Protein C , S Antithrombin III
![Page 20: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/20.jpg)
RADIOLOGYRADIOLOGY
ULTRASOUND (Duplex) VENOGRAPHY (rarely used) MRV ventilation-perfusion scanning ( for PE ) Nuclear venography
![Page 21: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/21.jpg)
![Page 22: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/22.jpg)
![Page 23: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/23.jpg)
![Page 24: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/24.jpg)
MANAGEMENT
![Page 25: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/25.jpg)
GENERAL MEASURESGENERAL MEASURES
1- Complete bed rest
2-The affected extremity should be elevated above the level of the heart until the oedema and tenderness subside .
![Page 26: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/26.jpg)
Anticoagulants Thrombolytics Prophylaxis
![Page 27: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/27.jpg)
I-AnticoagulantsI-Anticoagulants
Anticoagulants prevent thrombous propagation & allow endogenous lytic system to operate.
Aim :prevention of pulmonary embolism , since in the early stages the thrombus maybe loose & poorly adherent to the vessel wall.
![Page 28: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/28.jpg)
ContraindicationContraindication
1-recent surgery, especially to eye or CNS.2-Pre_existing hemorrhagic state e.g. Liver ds Renal Failure Hemophilia Thrombocytopenia3-Pre_existing structural lesions e.g. Peptic Ulcer4-Recent cerebral hemorrhage.5-Uncontrolled HPN.
![Page 29: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/29.jpg)
11--HeparinHeparin
Mech. Of actionMech. Of action Standard Heparin (SH)Standard Heparin (SH)
produces its anticoagulant effect by potentiating the activity of anti-thrombin which will inhibit procoagulant enzymatic activity of factors IIa ,VIIa ,IXa ,Xa ,XIa.
LMWH LMWH augment anti-thrombin activity against factor Xa.
![Page 30: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/30.jpg)
Advantages of LMWH over SHAdvantages of LMWH over SH
1-LMWH has a high bioavailability after SC injection so its given either as a fixed or weight-related dose .Therefore ,The plasma LMWH level does not need to be measured.
2-The incidence of thrombocytopenia is less with LMWH than SH.
![Page 31: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/31.jpg)
3-LMWH is reported to be as effective as or better than SH in preventing extension or recurrence of venous thrombosis.
![Page 32: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/32.jpg)
Route of Admn. & Dose
Heparin…(IV) as an initial bolus of 7500 to 10,000 IU followed by a continuous infusion of 1000 to 1500 IU/h.
The rate of heparin infusion should be adjusted so that the active aPTT is approximately twice the control value.
![Page 33: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/33.jpg)
S/E…in less than 5% of patients ,heparin therapy may cause thrombocytopenia. Infrequently ,these pt develop arterial thrombosis & Ischemia
![Page 34: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/34.jpg)
22--WARFARINWARFARIN
Mech. Of action.. Warfarin inhibit vit K-dependant
carboxylation of factors II ,VII ,IX ,X in the liver.
Warfarin is administered during the 1st wk of treatment with heparin &maybe started as early as the 1st day of heparin treatment if the aPTT is therapeutic.
![Page 35: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/35.jpg)
Why to overlap Heparin ttt with oral anticoagulant therapy??
This because of the delayed effect of warfarin.
SO…Overlap is important for at least 4-5 days
Dose of warfarin should be adjusted to maintain the thrombin time at an INR of 2-3
![Page 36: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/36.jpg)
Duration of anti-coagulant therapy
1st attack 3 M
2nd attack 1 year
3rd attack Life
![Page 37: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/37.jpg)
BUT…What if treatment with anti-BUT…What if treatment with anti-coagulant is contraindicatedcoagulant is contraindicated??????
IVC filter.
![Page 38: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/38.jpg)
II-ThrombolyticsII-Thrombolytics
StreptokinaseUrokinaseTissue Plasminogen
Activator
![Page 39: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/39.jpg)
There is no evidence that thrombolytic therapy is more effective than anti-coagulants in preventing pulmonary embolism!!
HOWEVER…early administration of thrombolytic drugs may accelerate clot lysis .
![Page 40: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/40.jpg)
III-ProphylaxisIII-Prophylaxis
ALL PATIENTS ADMITTED TO HOSPITAL SHOULD BE ASSESSED FOR THEIR RISK OF VENOUS THROMBOSIS.
![Page 41: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/41.jpg)
Mechanical:Mechanical: -early mobilization
-leg raising.
- graduated compression (TED) stocking.
DrugsDrugs (anti-coagulants).
![Page 42: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/42.jpg)
Moderate risk of DVTHigh risk of DVT
Major surgery in patient>40 years or with other risk factorMajor medical illness
e.g. heart failure
chest infection
malignancy
inflammatory bowel disease
Hip or knee surgery Major abdominal or pelvic surgery for malignancy or with history of DVT
![Page 43: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/43.jpg)
Category Frequency of Calf Vein Thrombosis
Frequency of Proximal Vein Thrombosis
Frequency of Fatal PE
High-risk 40-80% 10-30% >1%
Moderate-risk
10-40% 1-10% 0.1-1%
Low-risk >10% >1% >0.1%
![Page 44: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/44.jpg)
Anti-coagulantsAnti-coagulants
Heparin(5000 units 2h prior to surgery then 5000 units every 8-12h post operatively) reduces the risk of DVT ass. With thoracic & abdominal surgery & with prolonged bed rest.
LMWHs have been shown to prevent DVT in pt undergoing general or orthopedic surgery.
![Page 45: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/45.jpg)
Warfarin in a dose that yields apt equivalent to an INR of 2-3 is effective in preventing DVT ass. With bone fractures & orthopedic surgery.
Warfarin is started the night before surgery & continued.
![Page 46: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/46.jpg)
BUT..WHAT IF THE ANTICOAGULANT IS C/I???
External pneumatic compression devices applied to the legs are used to prevent DVT when even low doses of heparin or warfarin might cause serious bleeding ,as during neurosurgery or transurethral resection of the prostate
![Page 47: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/47.jpg)
What Is New ?
![Page 48: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/48.jpg)
PREVENTION AND TREATMENT OF VENOUS
THROMBOEMBOLISM
International Consensus Statement
(Guidelines according to scientific evidence)
(Int. Angiol., June 2006)
![Page 49: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/49.jpg)
64 international vascular experts 52 major centers worldwide DVT Registry 2001 – 2005 Meta – analysis of 116 studies Prevention and treatment policies
International Consensus Statement
Reviewed/modified
![Page 50: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/50.jpg)
![Page 51: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/51.jpg)
![Page 52: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/52.jpg)
![Page 53: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/53.jpg)
GENERAL AND VASCULAR SURGICAL PATIENTS
![Page 54: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/54.jpg)
THE RISKTHE RISK
Known clinical risk factors allow for classification of patients into high, medium or low risk of developing VTE
the risk continues after discharge from hospital.
Despite the use of intra-operative heparin or other perioperative antithrombotic substances, vascular surgical patients are at moderate risk
![Page 55: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/55.jpg)
The incidence of postoperative asymptomatic DVT is of the order of 18% in patients having abdominal vascular
surgery 15% for those having peripheral vascular
reconstruction The risk of VTE in patients undergoing
laparoscopic surgery appears to be low.
![Page 56: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/56.jpg)
Obesity is an independent risk factor for sudden post-operative fatal PE.
Bariatric surgery is associated with clinical VTE in 1.2% of cases and with fatal PE in 0.3%.
![Page 57: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/57.jpg)
ProphylaxisProphylaxis
low dose unfractionated heparin (LDUH) (5000 IU 8 or 12 hourly subcutaneously) was
found to reduce both DVT and fatal PE LMWH
not only reduces the incidence of fatal PE but also the overall surgical mortality as compared to controls without prophylaxis.
![Page 58: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/58.jpg)
dextrandextran The preventive effect of dextran on fatal PE
has been updated and verified. It appears that fibrin formed in the presence of dextran is not cross-linked so that it is easily lysed by the body’s natural fibrinolytic activity.
fluid overload and anaphylactoid reactions
![Page 59: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/59.jpg)
Graduated elastic compression (GEC) Graduated elastic compression (GEC) stockings reduce the incidence of
asymptomatic DVT by approximately 50-60%
Intermittent pneumatic compression Intermittent pneumatic compression (IPC)(IPC) reduces the incidence of asymptomatic DVT
by approximately 69%
![Page 60: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/60.jpg)
AspirinAspirin reduces DVT by 30% and PE by 50%
Combined modalities.Combined modalities. Evidence from randomized controlled
studies shows that combinations of prophylactic methods are more effective than using each method
![Page 61: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/61.jpg)
RecommendationsRecommendations
Low-risk patientsLow-risk patients (without risk factors undergoing minor
surgery.)
GEC stockings early ambulation adequate hydration
![Page 62: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/62.jpg)
Moderate-risk patientsModerate-risk patients
(over the age of 40 years undergoing major
surgery for benign disease ( LDUH 5000 units commenced pre-
operatively and continued 2X -3X daily
OR LMWH initiated and dosed according to
manufacturers
If Bleeding Risk: IPC with GEC compression used
continuously until the patient is ambulant
![Page 63: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/63.jpg)
High- risk patientsHigh- risk patients (aged over 60 years with additional risk
factors( LDUH (5000 units commenced two hours
before operation and continued post-operatively three times a day)
OR LMWH initiated and dosed according to the
manufacturer’s recommendations
![Page 64: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/64.jpg)
Laparoscopic surgery for major prolonged procedures will reduce venous flow in the legs and activate blood coagulation.
Prophylactic subcutaneous LDUH, LMWH, or IPC with GEC are recommended only in patients with additional risk factors
![Page 65: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/65.jpg)
BURNS
![Page 66: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/66.jpg)
THE RISKTHE RISK
The incidence of DVT using routine screening with duplex scanning in the absence of prophylaxis varies between 6% and 27%
Symptomatic VTE occurs in in 2.4% to 7.0% of patients.
![Page 67: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/67.jpg)
RecommendationsRecommendations
Drug: LMWH
Initiation: as soon as it is considered safe to
do so Duration:
as long as the patient remains at risk
![Page 68: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/68.jpg)
CANCER PATIENTS
![Page 69: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/69.jpg)
THE RISKTHE RISK
The risk of thromboembolic disease varies by type of malignancy 120 per 10,000 patients for ovarian
malignancy 117 per 10,000 for primary brain
malignancy 110 per 10,000 for pancreatic cancer
In OR the risk is 2X compared to Normal Patient
![Page 70: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/70.jpg)
patients receiving chemotherapy appear to have a therapy-associated increased rate of VTE
tumor and stage-dependent. Patients who received radiotherapy had a
higher frequency of VTE within three months of therapy and surgery compared with those who did not
![Page 71: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/71.jpg)
PROPHLAXISPROPHLAXIS
Surgical patients LDUH reduces the risk of DVT and fatal PE
in patients with malignancy having surgery LMWH is at least as effective as LDUH. Continuation of LMWH for four weeks after
discharge home reduces the risk of asymptomatic DVT as demonstrated by venography from 13.8% to 5.5%
![Page 72: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/72.jpg)
Medical cancer patients LMWH is effective for preventing
thromboembolic disease associated with acute medical illness
in 311 patients with metastatic breast cancer receiving chemotherapy randomised to low dose warfarin (INR between 1.3 and 1.9)
![Page 73: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/73.jpg)
Patients receiving radiotherapy Although patients who receive radiotherapy
have a higher frequency of VTE within three months of therapy and surgery compared with those who do no
there are no studies on the value of routine thromboprophylaxis in those receiving radiotherapy. Such studies need to be performed
![Page 74: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/74.jpg)
with central venous catheters cancer patients with central venous catheters
have a high frequency for development of VTE
The use of LMWH (Dalteparin sodium 2500 units once daily) has been shown to be effective in reducing venographic thrombosis from 62% to 6%
![Page 75: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/75.jpg)
Warfarin (1mg per day) has been shown to be effective in reducing all venographic thrombosis from 37% to 9.55
![Page 76: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/76.jpg)
RecommendationsRecommendations
Surgical: LDUH (5000 IU 8-hourly commenced prior
to operation) LMWH
![Page 77: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/77.jpg)
For patients at high risk for development of thromboembolic disease in the post-discharge period those with large volume residual malignant
disease previous history of venous thromboembolic
disease) prolonged thromboprophylaxis with
enoxaparin 40mg once daily for up to 4 weeks after operation should be considered
![Page 78: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/78.jpg)
In ambulant non-surgical cancer patients, data are available only for those with advanced breast cancer receiving chemotherapy In these patients,
use of vitamin K antagonists to maintain an INR of between 1.3 and 1.9 may be considered
![Page 79: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/79.jpg)
For cancer patients hospitalised with acute medical illness, thromboprophylaxis should be based on the risk for VTE determined by the acute medical co-morbidity. LMWH LDUH should be used (5000 IU 8-hourly)
![Page 80: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/80.jpg)
For cancer patients with central venous catheters, routine use of thromboprophylaxis to prevent central venous catheter associated thrombosis is not recommended
![Page 81: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/81.jpg)
MULTIPLE TRAUMA
![Page 82: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/82.jpg)
THE RISKTHE RISK
The incidence of DVT in patients who have sustained major trauma is in excess of 50%
PE is the third leading cause of death in those who survive beyond the first day
The risk is particularly high in patients with spinal cord injury, pelvic fracture and those needing surgery
![Page 83: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/83.jpg)
RecommendationsRecommendations
LMWH starting as soon as bleeding risk is acceptable
or IPC in the presence of contraindications to LMWH and continued until full ambulation.
![Page 84: DVT Current Concept](https://reader035.vdocuments.net/reader035/viewer/2022081505/554b51d1b4c905e9388b4930/html5/thumbnails/84.jpg)
THANK YOUTHANK YOU